science

Managed Access Programs

Sanofi Managed Access Programs1 (MAPs) provides early access to investigational medicines and medicines for which a marketing authorization application is ongoing to certain patients who cannot enroll in an ongoing clinical trial.

MAPs address the unmet medical need for patients affected by life-threatening, or seriously debilitating illnesses by making such medicines available to eligible patients.

Important Update: Sanofi has simplified MAP data retention; all physician and patient data will now be kept for 10 years after the country MAP closure. Please ensure that you inform your patient(s) of this change. ​In order to exercise your rights or ask any question, you should reach the Affiliate in your country or use the form available here.

1Sanofi “Managed Access” terminology covers many locally defined pre-approval access routes including, but not limited to Compassionate Use (CU) and Expanded Access Programs (EAP).